Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trial

The twice-yearly injectable drug completely prevented HIV infections in a Phase 3 trial involving over 5,300 women in Africa.

The trial found zero HIV infections among women who received lenacapavir compared to those on daily Truvada or Descovy.
Independent monitors recommended ending the blind phase and offering the drug to all participants due to the compelling results.
Gilead's stock surged over 8% following the announcement, reflecting investor optimism.
Further trials are underway to test lenacapavir's efficacy in other populations, with results expected by late 2024 or early 2025.
Regulatory approval will be sought after additional studies, potentially making lenacapavir a new standard in HIV prevention.